Mar. 16, 2019 – Hence the interest in a recent announcement by the Food and Drug Administration (FDA) in America that it had approved a new drug for patients with “treatment-resistant” depression, defined as having not responded adequately to at least two previous antidepressants. Of particular note is that it is based on ketamine, a recreational drug. Esketamine, as the chemical is known, is branded as Spravato by its developer, Janssen Pharmaceuticals, a branch of Johnson & Johnson.
SHE’D NEVER DRAG HIM DOWN – April 10, 2024 - Ariana Grande is a…
WHAT GOES AROUND... – April 9, 2024 - In a cover profile of RDJ…
VIDEO – ONE MARRIAGE AT A TIME – April 10, 2024 - “Alcohol made…
HAS HE MADE HIS AMENDS? – April, 2024 - “Manson hasn’t been out on…
VIDEO – IN ALL OUR ENDEAVORS – April 9, 2024 - Within the structure…